Terms: = Liver cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2
143 results:
1. Discovery of novel fgfr4 inhibitors through a build-up fragment strategy.
Kim J; Im CG; Oh K; Lee JM; Al-Rubaye F; Min KH
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2343350. PubMed ID: 38655602
[TBL] [Abstract] [Full Text] [Related]
2. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.
Lin K; Xia B; Wang X; He X; Zhou M; Lin Y; Qiao Y; Li R; Chen Q; Li Y; Feng J; Chen T; Chen C; Li X; Zhang H; Lu L; Liu B; Zhang X
J Transl Med; 2024 Apr; 22(1):349. PubMed ID: 38610029
[TBL] [Abstract] [Full Text] [Related]
3. Development of Highly Potent and Selective Covalent fgfr4 Inhibitors Based on S
Schwarz M; Kurkunov M; Wittlinger F; Rudalska R; Wang G; Schwalm MP; Rasch A; Wagner B; Laufer SA; Knapp S; Dauch D; Gehringer M
J Med Chem; 2024 Apr; 67(8):6549-6569. PubMed ID: 38604131
[TBL] [Abstract] [Full Text] [Related]
4. Blocking of fgfr4 signaling by F30 inhibits hepatocellular carcinoma cell proliferation through HMOX1-dependent ferroptosis pathway.
Huang F; Shi X; Hu M; Yan H; Li X; Ding Y; Zheng X; Cai X; Dai S; Xia Q; Cai Y
Eur J Pharmacol; 2024 May; 970():176493. PubMed ID: 38484925
[TBL] [Abstract] [Full Text] [Related]
5. Design, synthesis, and biological evaluation of selective covalent inhibitors of fgfr4.
Chen X; Li H; Lin Q; Dai S; Qu L; Guo M; Zhang L; Liao J; Wei H; Xu G; Jiang L; Chen Y
Eur J Med Chem; 2024 Mar; 268():116281. PubMed ID: 38432058
[TBL] [Abstract] [Full Text] [Related]
6. FGF19-Based Mini Probe Targeting fgfr4 for Diagnosis and Surgical Navigation of Hepatocellular Carcinoma.
Cai J; Lian C; Lu Z; Shang Q; Wang L; Han Z; Gu Y
J Med Chem; 2024 Mar; 67(5):3764-3777. PubMed ID: 38385325
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.
Yang F; Lin Q; Song X; Huang H; Chen X; Tan J; Li Y; Zhou Y; Tu Z; Du H; Zhang ZM; Ortega R; Lin X; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2024 Feb; 67(4):2667-2689. PubMed ID: 38348819
[TBL] [Abstract] [Full Text] [Related]
8. Targeting the FGF19-fgfr4 pathway for cholestatic, metabolic, and cancerous diseases.
Li X; Lu W; Kharitonenkov A; Luo Y
J Intern Med; 2024 Mar; 295(3):292-312. PubMed ID: 38212977
[TBL] [Abstract] [Full Text] [Related]
9. FGF19/fgfr4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
[TBL] [Abstract] [Full Text] [Related]
10. Insight into the design of fgfr4 selective inhibitors in cancer therapy: Prospects and challenges.
Chen X; Huang Y; Chen B; Liu H; Cai Y; Yang Y
Eur J Med Chem; 2024 Jan; 263():115947. PubMed ID: 37976704
[TBL] [Abstract] [Full Text] [Related]
11. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating fgfr4 expression.
Guo W; Li S; Qian Y; Li L; Wang F; Tong Y; Li Q; Zhu Z; Gao WQ; Liu Y
Clin Transl Med; 2023 Oct; 13(10):e1452. PubMed ID: 37846441
[TBL] [Abstract] [Full Text] [Related]
12. EGFR Inhibition Overcomes Resistance to fgfr4 Inhibition and Potentiates fgfr4 Inhibitor Therapy in Hepatocellular Carcinoma.
Shen B; Shi JP; Zhu ZX; He ZD; Liu SY; Shi W; Zhang YX; Ying HY; Wang J; Xu RF; Fang F; Chang HX; Chen Z; Zhang NN
Mol Cancer Ther; 2023 Dec; 22(12):1479-1492. PubMed ID: 37710057
[TBL] [Abstract] [Full Text] [Related]
13. Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel fgfr4 inhibitors for the treatment of colorectal cancer.
Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
Eur J Med Chem; 2023 Nov; 259():115703. PubMed ID: 37556948
[TBL] [Abstract] [Full Text] [Related]
14. Humanized disulfide-stabilized diabody against fibroblast growth factor-2 inhibits PD-L1 expression and epithelial-mesenchymal transition in hepatoma cells through STAT3.
Sun H; Song X; Li C; Li Q; Liu S; Deng N
IUBMB Life; 2023 Nov; 75(11):957-968. PubMed ID: 37489553
[TBL] [Abstract] [Full Text] [Related]
15. Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of fgfr4 in wild-type and gatekeeper mutants.
Yang Y; He X; Li Z; Ran K; Wang N; Zhao L; Liu Z; Zeng J; Chang B; Feng Q; Zhang Q; Yu L
Eur J Med Chem; 2023 Oct; 258():115628. PubMed ID: 37437349
[TBL] [Abstract] [Full Text] [Related]
16. Small Extracellular Vesicle-Derived vWF Induces a Positive Feedback Loop between Tumor and Endothelial Cells to Promote Angiogenesis and Metastasis in Hepatocellular Carcinoma.
Wong SWK; Tey SK; Mao X; Fung HL; Xiao ZJ; Wong DKH; Mak LY; Yuen MF; Ng IO; Yun JP; Gao Y; Yam JWP
Adv Sci (Weinh); 2023 Sep; 10(26):e2302677. PubMed ID: 37387563
[TBL] [Abstract] [Full Text] [Related]
17. FGF19-Induced Inflammatory CAF Promoted Neutrophil Extracellular Trap Formation in the liver Metastasis of Colorectal cancer.
Li C; Chen T; Liu J; Wang Y; Zhang C; Guo L; Shi D; Zhang T; Wang X; Li J
Adv Sci (Weinh); 2023 Aug; 10(24):e2302613. PubMed ID: 37345586
[TBL] [Abstract] [Full Text] [Related]
18. Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent fgfr4 inhibitors.
Wang M; Lan L; Wang YW; Zhang JY; Shi L; Sun LP
Bioorg Med Chem; 2023 May; 87():117298. PubMed ID: 37196426
[TBL] [Abstract] [Full Text] [Related]
19. fgfr4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.
Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A
J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881
[TBL] [Abstract] [Full Text] [Related]
20. Minimally Invasive Versus Open liver Resections for Hepatocellular Carcinoma in Patients With Metabolic Syndrome.
Berardi G; Ivanics T; Sapisochin G; Ratti F; Sposito C; Nebbia M; D'Souza DM; Pascual F; Tohme S; D'Amico FE; Alessandris R; Panetta V; Simonelli I; Del Basso C; Russolillo N; Fiorentini G; Serenari M; Rotellar F; Zimitti G; Famularo S; Hoffman D; Onkendi E; Lopez-Ben S; Caula C; Rompianesi G; Chopra A; Abu Hilal M; Torzilli G; Corvera C; Alseidi A; Helton S; Troisi RI; Simo K; Conrad C; Cescon M; Cleary S; Kwon CHD; Ferrero A; Ettorre GM; Cillo U; Geller D; Cherqui D; Serrano PE; Ferrone C; Mazzaferro V; Aldrighetti L; Kingham TP
Ann Surg; 2023 Nov; 278(5):e1041-e1047. PubMed ID: 36994755
[TBL] [Abstract] [Full Text] [Related]
[Next]
